Pharmacare News Bulletins

Pharmacists' Bulletins Volume Twelve 2012

December Bulletin Vol. 12 - 12
Update of Criteria and New ESD Form for Osteoporosis Therapies; New Exception Status Benefits: Brilinta®, Saphris®; Non-Insured Products: Resotran®

Bulletin Attachments:

• Pharmacare Payment Schedule
• Osteoporosis Form

November Bulletin Vol. 12 - 11
New Exception Status Benefit: Levemir; Antiviral Therapies for Influenza; Criteria Update – Infliximab, Capecitabine; Hp-Pac Benefit Status

Bulletin Attachments:

• Pharmacists’ Guide

September Bulletin Vol. 12 - 10
Billing of Claim Cost Exceeding $9,999.99; Dabigatran (Pradax®) or Rivaroxaban (Xarelto®) Form

Bulletin Attachments:

• Request for coverage of Dabigatran (Pradax) and Rivaroxaban (Xarelto) in Atrial Fibrillation Form

September Bulletin Vol. 12 - 09
New Exception Status Benefits: Xarelto®, Incivek®, Victrelis®; Criteria Updates: Pegasys RBV®, Pegetron®, Afinitor®

August Bulletin Vol. 12 - 08
Pharmacists’ Guide - Important Reminders; Understanding Generic Drugs; Transition Fees

Bulletin Attachments:

• Lantus Information

July Bulletin Vol. 12 - 07
Criteria Updates: Xarelto®, Sutent®; Changes to Generic Drug Pricing; Standardization of Package Sizes

Bulletin Attachments:

• Prescriber List
• Reimbursement List

June Bulletin Vol. 12 - 06
New Exception Status Benefits: Banzel®, Pradax®; Criteria Updates: Xeloda®, Gleevec®; Transition Fees

Bulletin Attachments:

• Request for Coverage of Dabigatran (Pradax®) Form
• Pradax® Information Sheet

May Bulletin Vol. 12 - 05
Pharmacy Provider Numbers; Criteria Updates: Olanzapine, Terbinafine, Revlimid®; Palliative Home Care Drug Coverage Program

April Bulletin Vol. 12 - 04
Cholinesterase Inhibitors Exception Status Criteria and Process Revisions; Palliative Home Care Drug Coverage Program Update; Understanding Generic Drugs

Bulletin Attachments:

• First Request for Cholinesterase Inhibitor
• Request for Renewal of a Cholinesterase Inhibitor
• Generic Drugs: Your Questions Answered
• Similarities and Differences Between Brand Name and Generic Drugs
• What are Bioavailability and Bioequivelance?

February Bulletin Vol. 12 - 03
OxyContin®/OxyNEO® Communication; Transition Fees; Changes to the Nova Scotia Formulary on the Pharmacare Website

February Bulletin Vol. 12 - 02
Palliative Home Care Drug Program

Bulletin Attachments:
Palliative Home Care Medication Authorization Form
Direct Deposit Form

January Bulletin Vol. 12 - 01
Calcitonin Intranasal Criteria Code; Transition Fees; Changes to the Formulary on the Pharmacare Website

Bulletin Attachment
Prescriber List - January 2012

Pharmacists' Bulletins Volume Eleven 2011

Coverage for Antiviral Therapies for Influenza-Like Illness (ILI); Changes to Generic Drug Pricing

Bulletin Attachments:
a) Payment Schedules - 2012
b) Discontinued Products
c) Reimbursement List (Jan. 1, 2012)
d) Reimbursement List (Feb. 1, 2012)

October Bulletin Vol. 11 - 09
Automation of Exception Status Requests; Drug Costs Billed to the Pharmacare Programs; Transition Fees

Bulletin Attachments:
CADTH Optimal Therapy Newsletter
a) Type 2 Diabetes – Second- and Third-Line Therapies
b) When Metformin Alone is Not Enough

September Bulletin Vol. 11 - 08
 Insured Professional Services

August Bulletin Vol. 11 - 07
Formulary Updates; Fair Drug Pricing Legislation Clarification; Pharmacare Reimbursement; New Prescribers

Bulletin Attachments:
Request for Credit: Injectable Medication and Ostomy Supplies

July Bulletin Vol. 11 - 06
Update on Exception Status Drug Requests; Changes to Billing for Methadone Oral Liquid; Auditors Corner

Bulletin Attachments:
Pharmacare Tariff Agreement
Confirmation of Agreement
Prescribers List

June Bulletin Vol. 11 - 05 
Changes to Generic Drug Pricing

May Bulletin Vol. 11 - 04
Formulary Updates;
Change in Notification: New Interchangeable Products;
Pharmacare Reimbursement;
New Prescribers

April Bulletin Vol. 11 - 03 
Pharmacist Prescribing;
New Benefits and Interchangeable Products;
Billing Pharmacare Clients for MAC or Special MAC Drugs

Bulletin Attachment: Pharmacist Exception Status Drug Request Form

March Bulletin Vol. 11 - 02
Fragmin Pre-filled Syringe DIN Change;
New Prescribers; 
Product Name and Manufacturer Change;
Change in MAC and Special MAC Pricing

January Bulletin Vol. 11 - 01
Change to Exception Status - Cesamet®;
Update on Proton Pump Inhibitors (PPIs);
Formulary Updates; 
Pharmacare Reimbursement

Physicians' Bulletins Volume Twelve 2012

December Bulletin Vol. 12 - 11
Update of Criteria and New ESD Form for Osteoporosis Therapies; New Exception Status Benefits: Brilinta®, Saphris®; Non-Insured Products: Resotran®

Bulletin Attachment:

• Osteoporosis Form

November Bulletin Vol. 12 - 10
New Exception Status Benefit: Levemir; Antiviral Therapies for Influenza; Criteria Update – Infliximab, Capecitabine; Hp-Pac Benefit Status.

September Bulletin Vol. 12 - 09
Dabigatran (Pradax®) or Rivaroxaban (Xarelto®) Form

Bulletin Attachments:

• Request for coverage of Dabigatran (Pradax) and Rivaroxaban (Xarelto) in Atrial Fibrillation Form

September Bulletin Vol. 12 - 08
New Exception Status Benefits: Xarelto®, Incivek®, Victrelis®; Criteria Updates: Pegasys RBV®, Pegetron®, Afinitor®

August Bulletin Vol. 12 - 07
New Exception Status Benefits: Lantus®; Understanding Generic Drugs

Bulletin Attachments:

• Lantus Information

July Bulletin Vol. 12 - 06
New Exception Status Benefits; Criteria Updates: Xarelto®, Sutent®; New Diabetic Products; Non-Insured Products

June Bulletin Vol. 12 - 05
New Exception Status Benefits: Banzel®, Pradax®; Criteria Updates: Xeloda®, Gleevec®; Non-Insured Products

• Request for Coverage of Dabigatran (Pradax®) Form
• Pradax® Information Sheet

May Bulletin Vol. 12 - 04
Criteria Updates: Olanzapine, Terbinafine, Revlimid®; New Exception Status Benefits; New Products; Non-Insured Products

April Bulletin Vol. 12 - 03
Cholinesterase Inhibitors Exception Status Criteria and Process Revisions; Understanding Generic Drugs

• First Request for Cholinesterase Inhibitor
• Request for Renewal of a Cholinesterase Inhibitor
• Generic Drugs: Your Questions Answered
• Similarities and Differences Between Brand Name and Generic Drugs
• What are Bioavailability and Bioequivelance?

March Bulletin Vol. 12 - 02
OxyContin/OxyNEO Communication; Palliative Home Care Drug Coverage Program; Changes to the Nova Scotia Formulary on the Pharmacare Website

Bulletin Attachments:

• Lantus Information

February Bulletin Vol. 12 - 01
Calcitonin Intranasal Criteria Code; Non-Insured Products; Changes to the Formulary on the Pharmacare Website

Physicians' Bulletins Volume Eleven 2011

December Bulletin Vol. 11 - 07
Coverage for Antiviral Therapies for Influenza-Like Illness (ILI); Formulary Updates

October Bulletin Vol. 11 - 06
Automation of Exception Status Requests; New Exception Status Benefit ; Non-Insured Products

Bulletin Attachments:
CADTH Optimal Therapy Newsletter
a) Type 2 Diabetes – Second- and Third-Line Therapies
b) When Metformin Alone is Not Enough

August Bulletin Vol. 11 - 05
New Exception Status Benefit ; Non-Insured Products

July Bulletin Vol. 11 - 04
Update on Exception Status Drug Requests; Formulary Updates; Reminder: Include CPSNS Number When Submitting Requests for Coverage of Exception Status Drugs

May Bulletin Vol. 11 - 03
New Products;
New Exception Status Benefit;
Non-Insured Products

April Bulletin Vol. 11 - 02
Formulary Updates; Criteria Update - Humira; New Exception Status Benefits; Non-Insured Products

February Bulletin Vol. 11 - 01
Change to Exception Status - Cesamet®; Update on Proton Pump Inhibitors (PPIs); Formulary Updates